美国索赔数据库中新型冠状病毒感染疫苗接种后非感染性葡萄膜炎的风险
本研究利用美国索赔数据库,采用回顾性匹配队列和自身对照病例系列分析,评估无葡萄膜炎病史者接种新冠疫苗后非感染性葡萄膜炎风险。匹配队列调整后HR为0.91(95%CI 0.75-1.10;P=0.33),自身对照病例系列IRR为1.05(95%CI 0.89-1.23;P=0.57)。5-44岁亚组IRR为1.40(95%CI 1.04-1.87;P=0.024)。
要点
- 匹配队列分析未发现接种新冠疫苗后非感染性葡萄膜炎风险升高(调整后HR 0.91,95%CI 0.75-1.10)。
- 自身对照病例系列分析整体IRR为1.05(95%CI 0.89-1.23),未达统计学显著。
- 5-44岁亚组IRR为1.40(95%CI 1.04-1.87;P=0.024),作者认为需进一步研究。
核心结论
- 匹配队列和自身对照病例系列分析整体均未检测到无葡萄膜炎病史者接种新冠疫苗后非感染性葡萄膜炎风险升高,为疫苗安全性提供了 reassurance。
- 最年轻亚组(5-44岁)发现风险升高,作者认为可能反映年轻个体更强的免疫反应,需进一步研究。
研究设计与样本
- 回顾性匹配队列研究和自身对照病例系列分析,使用OptumLabs Data Warehouse的索赔数据,时间范围为2020年12月11日至2021年11月30日。
- 匹配队列分析纳入在2020年12月11日前连续参保730天且在研究期间接种新冠疫苗的患者,与2018年和2019年参保的未接种新冠疫苗的历史队列进行匹配。
- 自身对照病例系列分析纳入接种队列中在研究期间发生非感染性葡萄膜炎事件的个体;有葡萄膜炎病史者被排除。
- 匹配队列分析共纳入4 611 378例患者,每队列2 305 689例;自身对照病例系列分析纳入686例患者。
主要发现
- 匹配队列分析中,新冠疫苗接种组与未接种组比较,非感染性葡萄膜炎发病的调整后HR为0.91(95%CI 0.75-1.10;P=0.33)。
- 自身对照病例系列分析中,接种后风险期与对照间期比较,非感染性葡萄膜炎风险的IRR为1.05(95%CI 0.89-1.23;P=0.57)。
- 5至44岁亚组发现风险升高,IRR为1.40(95%CI 1.04-1.87;P=0.024)。
关键数值与推荐
- 非感染性葡萄膜炎通过国际疾病分类第十版编码识别。
- 匹配队列模型调整了年龄、近期接种非新冠疫苗、皮质类固醇或免疫抑制剂使用以及吸烟史。
- 按疫苗类型和年龄组进行了亚组分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出最年轻亚组风险升高的发现需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess noninfectious uveitis (NIU) risk after coronavirus disease 2019 (COVID-19) vaccination in patients without a history of uveitis. DESIGN: A retrospective matched cohort study and self-controlled case series (SCCS) analysis using a longitudinal data asset with claims data from the OptumLabs Data Warehouse from December 11, 2020, through November 30, 2021. PARTICIPANTS: The matched cohort analysis included patients continuously enrolled for 730 days before December 11, 2020, who received a COVID-19 vaccination during the study period. This COVID-19-vaccinated group was matched to a COVID-19-unvaccinated historical cohort enrolled in 2018 and 2019. The SCCS design included individuals from the vaccinated cohort who experienced an NIU event during the study period. Enrollees with a history of uveitis were excluded. METHODS: Hazard ratios (HRs) were calculated using Cox proportional hazards models in the matched cohort design. Incidence rate ratios (IRRs) comparing NIU incidence in exposed risk periods after vaccination and unexposed control periods within individuals were calculated using conditional Poisson regression models in the SCCS design. Models were adjusted for age, recent receipt of non-COVID-19 vaccinations, corticosteroid or immunosuppressive use, and smoking history. Subgroup analyses were conducted by vaccination type and age group. MAIN OUTCOME MEASURES: Rates of NIU identified with International Classification of Diseases, Tenth Revision, codes. RESULTS: The matched cohort analysis included 4 611 378 patients, with 2 305 689 per cohort. The adjusted HR comparing NIU incidence in the COVID-19-vaccinated and unvaccinated cohort was 0.91 (95% confidence interval [CI], 0.75-1.10; P = 0.33). The SCCS analysis included 686 patients. The IRR comparing NIU risk after vaccination with risk during control intervals was 1.05 (95% CI, 0.89-1.23; P = 0.57). An increased risk was found in the subgroup aged 5 to 44 years (IRR, 1.40; 95% CI, 1.04-1.87; P = 0.024). CONCLUSIONS: The matched cohort and SCCS analyses did not detect increased NIU risk after COVID-19 vaccination overall in individuals without history of uveitis, providing reassurance about the vaccine's safety. The finding of increased risk in the youngest subgroup suggests heightened immune responses in younger individuals, warranting further investigation. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Kumar A, Miller DC, Sun Y, et al. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database. Ophthalmology. 2023. PMID: 37480943. doi:10.1016/j.ophtha.2023.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。